349 related articles for article (PubMed ID: 31923744)
21. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
[TBL] [Abstract][Full Text] [Related]
22. Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer.
Micke P; Botling J; Mattsson JSM; Planck M; Tran L; Vidarsdottir H; Nodin B; Jirström K; Brunnström H
Sci Rep; 2019 Feb; 9(1):1319. PubMed ID: 30718697
[TBL] [Abstract][Full Text] [Related]
23. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
El Hag M; Schmidt L; Roh M; Michael CW
Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
[TBL] [Abstract][Full Text] [Related]
24. Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung.
Yanagita E; Imagawa N; Ohbayashi C; Itoh T
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):509-13. PubMed ID: 21415705
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL
Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384
[TBL] [Abstract][Full Text] [Related]
26. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
[TBL] [Abstract][Full Text] [Related]
27. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.
Kadota K; Nitadori J; Rekhtman N; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2015 Sep; 39(9):1170-80. PubMed ID: 25871623
[TBL] [Abstract][Full Text] [Related]
28. Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
Koyi H; Brandén E; Kasim I; Wilander E
Anticancer Res; 2018 Jun; 38(6):3341-3346. PubMed ID: 29848682
[TBL] [Abstract][Full Text] [Related]
29. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.
Sterlacci W; Savic S; Schmid T; Oberaigner W; Auberger J; Fiegl M; Tzankov A
Am J Clin Pathol; 2012 Jun; 137(6):946-56. PubMed ID: 22586054
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.
Zachara-Szczakowski S; Verdun T; Churg A
Hum Pathol; 2015 May; 46(5):776-82. PubMed ID: 25776027
[TBL] [Abstract][Full Text] [Related]
31. Use of dual-marker staining to differentiate between lung squamous cell carcinoma and adenocarcinoma.
Guo R; Tian Y; Zhang N; Huang H; Huang Y; Yang J
J Int Med Res; 2020 Apr; 48(4):300060519893867. PubMed ID: 31880186
[TBL] [Abstract][Full Text] [Related]
32. Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma.
Johnson H; Cohen C; Fatima N; Duncan D; Siddiqui MT
Acta Cytol; 2012; 56(6):596-602. PubMed ID: 23207437
[TBL] [Abstract][Full Text] [Related]
33. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.
Kriegsmann K; Cremer M; Zgorzelski C; Harms A; Muley T; Winter H; Kazdal D; Warth A; Kriegsmann M
Pathology; 2019 Apr; 51(3):240-245. PubMed ID: 30798982
[TBL] [Abstract][Full Text] [Related]
34. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
35. Brightfield multiplex immunohistochemistry with multispectral imaging.
Morrison LE; Lefever MR; Behman LJ; Leibold T; Roberts EA; Horchner UB; Bauer DR
Lab Invest; 2020 Aug; 100(8):1124-1136. PubMed ID: 32341516
[TBL] [Abstract][Full Text] [Related]
36. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
[TBL] [Abstract][Full Text] [Related]
37. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.
Ao MH; Zhang H; Sakowski L; Sharma R; Illei PB; Gabrielson E; Askin F; Li QK
Hum Pathol; 2014 May; 45(5):926-34. PubMed ID: 24746197
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.
Pelosi G; Fraggetta F; Pasini F; Maisonneuve P; Sonzogni A; Iannucci A; Terzi A; Bresaola E; Valduga F; Lupo C; Viale G
Am J Surg Pathol; 2001 Mar; 25(3):363-72. PubMed ID: 11224607
[TBL] [Abstract][Full Text] [Related]
39. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.
Kadivar M; Boozari B
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):191-5. PubMed ID: 22914608
[TBL] [Abstract][Full Text] [Related]
40. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
